ANXA1
Annexin A1
Also known as: ANX1, ANXA1_HUMAN, LPC1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P04083
- Gene
- ANXA1
- Ensembl
- ENSG00000135046
- Chromosome
- 9
- Canonical length
- 346 aa
- Protein class
- Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a membrane-localized protein that binds phospholipids. This protein inhibits phospholipase A2 and has anti-inflammatory activity. Loss of function or expression of this gene has been detected in multiple tumors. [provided by RefSeq, Dec 2014]
Canonical amino-acid sequenceUniProt
346 residues, UniProt reviewed canonical sequence.
>P04083|ANXA1
1 MAMVSEFLKQ AWFIENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKAIMVKGV
61 DEATIIDILT KRNNAQRQQI KAAYLQETGK PLDETLKKAL TGHLEEVVLA LLKTPAQFDA
121 DELRAAMKGL GTDEDTLIEI LASRTNKEIR DINRVYREEL KRDLAKDITS DTSGDFRNAL
181 LSLAKGDRSE DFGVNEDLAD SDARALYEAG ERRKGTDVNV FNTILTTRSY PQLRRVFQKY
241 TKYSKHDMNK VLDLELKGDI EKCLTAIVKC ATSKPAFFAE KLHQAMKGVG TRHKALIRIM
301 VSRSEIDMND IKAFYQKMYG ISLCQAILDE TKGDYEKILV ALCGGNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ANXA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 7,699 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 7,699 nTPM
- bone marrow: 2,012 nTPM
- vagina: 1,680 nTPM
- salivary gland: 1,501 nTPM
- tonsil: 1,393 nTPM
- cervix: 1,390 nTPM
Single-cell type
- esophageal apical cells: 89,659 nCPM
- esophageal suprabasal cells: 19,784 nCPM
- syncytiotrophoblasts: 10,181 nCPM
- ocular epithelial cells: 7,882 nCPM
- suprabasal keratinocytes: 6,802 nCPM
- epididymal basal cells: 5,147 nCPM
Immune cell
- basophil: 2,824 nTPM
- eosinophil: 2,233 nTPM
- total PBMC: 2,021 nTPM
- myeloid DC: 1,515 nTPM
- classical monocyte: 1,239 nTPM
- MAIT T-cell: 758 nTPM
Brain region
- medulla oblongata: 76 nTPM
- hypothalamus: 76 nTPM
- midbrain: 59 nTPM
- thalamus: 58 nTPM
- white matter: 48 nTPM
- spinal cord: 47 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ANXA1.
Disease | ImmuneIEDB
Conditions an epitope on ANXA1 was assayed in.
- rheumatoid arthritis B cell
- skin melanoma T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against ANXA1 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for ANXA1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
22 publications
- Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.
2008 · J Clin Oncol · RCR 3.6 · 158 citations - Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases.
2011 · Autoimmun Rev · RCR 2.8 · 90 citations - Immunobiomarkers in small cell lung cancer: potential early cancer signals.
2011 · Clin Cancer Res · RCR 2.2 · 83 citations - Annexin A1 and Autoimmunity: From Basic Science to Clinical Applications.
2018 · Int J Mol Sci · RCR 2.1 · 55 citations - Suppression of autoreactive T and B lymphocytes by anti-annexin A1 antibody in a humanized NSG murine model of systemic lupus erythematosus.
2020 · Clin Exp Immunol · RCR 1.1 · 24 citations
Show 17 more
- Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study.
2021 · Rheumatology (Oxford) · RCR 0.9 · 13 citations - Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma.
2020 · BMC Cancer · RCR 0.9 · 18 citations - Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
2017 · Autoimmunity · RCR 0.7 · 15 citations - Presence of auto-antibody against two placental proteins, annexin A1 and vitamin D binding protein, in sera of women with pre-eclampsia.
2013 · J Reprod Immunol · RCR 0.6 · 16 citations - Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
2014 · Tumour Biol · RCR 0.6 · 19 citations - Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome.
2016 · Biochem Med (Zagreb) · RCR 0.6 · 14 citations - Antibodies to human recombinant lipocortin-I in inflammatory bowel disease.
1993 · Clin Sci (Lond) · RCR 0.6 · 21 citations - Evidence for charge-based mimicry in anti dsDNA antibody generation.
2022 · J Autoimmun · RCR 0.5 · 5 citations - Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
2017 · Anticancer Res · RCR 0.3 · 9 citations - The presence of autoantibody to recombinant lipocortin-I in patients with psoriasis and psoriatic arthritis.
1990 · Br J Dermatol · RCR 0.3 · 9 citations - Detection of human anti-annexin autoantibodies by enzyme immunoassays.
1992 · J Immunoassay · RCR 0.3 · 9 citations - Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus.
2021 · Arch Immunol Ther Exp (Warsz) · RCR 0.3 · 3 citations - Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
2020 · Scand J Immunol · RCR 0.3 · 4 citations - The presence of autoantibody to lipocortin-I in autoimmune-prone MRL mice.
1992 · Autoimmunity · RCR 0.2 · 6 citations - Expression correlates between Annexin A1 and A2 autoantibodies in patients with Behçet's disease.
2018 · Biosci Rep · RCR 0.1 · 4 citations - Laboratory measurement of autoantibodies to Annexin A1: Review and measurements in health and COVID-19.
2024 · Transfus Apher Sci - Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma.
2025 · Adv Med Sci
Reference: B cellIEDB
1 publication
- Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis.
2020 · Arthritis Rheumatol · RCR 1.7 · 30 citations
Reference: T cellIEDB
1 publication
- High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
2012 · J Biol Chem · RCR 0.6 · 25 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.03
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.05
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- actin cytoskeleton organization
- adaptive immune response
- alpha-beta T cell differentiation
- arachidonate secretion
- cell surface receptor signaling pathway
- cellular response to glucocorticoid stimulus
- cellular response to vascular endothelial growth factor stimulus
- G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
- granulocyte chemotaxis
- inflammatory response
- innate immune response
- keratinocyte differentiation
- monocyte chemotaxis
- myoblast migration involved in skeletal muscle regeneration
- negative regulation of apoptotic process
- negative regulation of exocytosis
- negative regulation of interleukin-8 production
- negative regulation of T-helper 2 cell differentiation
- neutrophil activation
- neutrophil clearance
- neutrophil homeostasis
- peptide cross-linking
- phagocytosis
- positive regulation of cell migration involved in sprouting angiogenesis
- positive regulation of G1/S transition of mitotic cell cycle
- positive regulation of interleukin-2 production
- positive regulation of neutrophil apoptotic process
- positive regulation of T cell proliferation
- positive regulation of T-helper 1 cell differentiation
- positive regulation of vesicle fusion
- positive regulation of wound healing
- regulation of cell shape
- regulation of hormone secretion
- regulation of inflammatory response
- regulation of leukocyte migration
- signal transduction
- regulation of interleukin-1 production
Molecular functions
- cadherin binding involved in cell-cell adhesion
- calcium ion binding
- calcium-dependent phospholipid binding
- calcium-dependent protein binding
- lipid binding
- phosphatidylserine binding
- phospholipase A2 inhibitor activity
- phospholipid binding
- signaling receptor binding
Cellular components
- adherens junction
- apical plasma membrane
- basolateral plasma membrane
- cell surface
- cornified envelope
- cytoplasm
- cytosol
- early endosome membrane
- endosome
- extracellular exosome
- extracellular matrix
- extracellular region
- extracellular space
- focal adhesion
- lateral plasma membrane
- motile cilium
- nucleoplasm
- nucleus
- phagocytic cup
- plasma membrane
- sarcolemma
- vesicle
- vesicle membrane
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
- Acetylation
- Adaptive immunity
- Annexin
- Calcium
- Calcium/phospholipid-binding
- Cell membrane
- Cell projection
- Cilium
- Cytoplasm
- Cytoplasmic vesicle
- Disulfide bond
- Endosome
- Immunity
- Inflammatory response
- Innate immunity
- Isopeptide bond
- Membrane
- Metal-binding
- Nucleus
- Pharmaceutical
- Phospholipase A2 inhibitor
- Phosphoprotein
- Repeat
- Secreted
- Ubl conjugation
InteractionsUniProt · HPA
Protein binding partners of ANXA1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ANXA1 as an antibody target. Whether an autoantibody or antibody against ANXA1 could matter depends on whether native ANXA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ANXA1 is annotated at the cell surface, where native ANXA1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ANXA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...